Cargando…

Cardiovascular Effects of Pharmacological Targeting of Sphingosine Kinase 1

High blood pressure is a risk factor for cardiovascular diseases. Ang II (angiotensin II), a key pro-hypertensive hormone, mediates target organ consequences such as endothelial dysfunction and cardiac hypertrophy. S1P (sphingosine-1-phosphate), produced by Sphk1 (sphingosine kinase 1), plays a pivo...

Descripción completa

Detalles Bibliográficos
Autores principales: Józefczuk, Ewelina, Nosalski, Ryszard, Saju, Blessy, Crespo, Eva, Szczepaniak, Piotr, Guzik, Tomasz Jan, Siedlinski, Mateusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott, Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055939/
https://www.ncbi.nlm.nih.gov/pubmed/31838904
http://dx.doi.org/10.1161/HYPERTENSIONAHA.119.13450
_version_ 1783503452555444224
author Józefczuk, Ewelina
Nosalski, Ryszard
Saju, Blessy
Crespo, Eva
Szczepaniak, Piotr
Guzik, Tomasz Jan
Siedlinski, Mateusz
author_facet Józefczuk, Ewelina
Nosalski, Ryszard
Saju, Blessy
Crespo, Eva
Szczepaniak, Piotr
Guzik, Tomasz Jan
Siedlinski, Mateusz
author_sort Józefczuk, Ewelina
collection PubMed
description High blood pressure is a risk factor for cardiovascular diseases. Ang II (angiotensin II), a key pro-hypertensive hormone, mediates target organ consequences such as endothelial dysfunction and cardiac hypertrophy. S1P (sphingosine-1-phosphate), produced by Sphk1 (sphingosine kinase 1), plays a pivotal role in the pathogenesis of hypertension and downstream organ damage, as it controls vascular tone and regulates cardiac remodeling. Accordingly, we aimed to examine if pharmacological inhibition of Sphk1 using selective inhibitor PF543 can represent a useful vasoprotective and cardioprotective anti-hypertensive strategy in vivo. PF543 was administered intraperitoneally throughout a 14-day Ang II-infusion in C57BL6/J male mice. Pharmacological inhibition of Sphk1 improved endothelial function of arteries of hypertensive mice that could be mediated via decrease in eNOS (endothelial nitric oxide synthase) phosphorylation at T495. This effect was independent of blood pressure. Importantly, PF543 also reduced cardiac hypertrophy (heart to body weight ratio, 5.6±0.2 versus 6.4±0.1 versus 5.9±0.2 mg/g; P<0.05 for Sham, Ang II+placebo, and Ang II+PF543-treated mice, respectively). Mass spectrometry revealed that PF543 elevated cardiac sphingosine, that is, Sphk1 substrate, content in vivo. Mechanistically, RNA-Seq indicated a decreased expression of cardiac genes involved in actin/integrin organization, S1pr1 signaling, and tissue remodeling. Indeed, downregulation of Rock1 (Rho-associated coiled-coil containing protein kinase 1), Stat3 (signal transducer and activator of transcription 3), PKC (protein kinase C), and ERK1/2 (extracellular signal-regulated kinases 1/2) level/phosphorylation by PF543 was observed. In summary, pharmacological inhibition of Sphk1 partially protects against Ang II–induced cardiac hypertrophy and endothelial dysfunction. Therefore, it may represent a promising target for harnessing residual cardiovascular risk in hypertension.
format Online
Article
Text
id pubmed-7055939
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott, Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-70559392020-03-19 Cardiovascular Effects of Pharmacological Targeting of Sphingosine Kinase 1 Józefczuk, Ewelina Nosalski, Ryszard Saju, Blessy Crespo, Eva Szczepaniak, Piotr Guzik, Tomasz Jan Siedlinski, Mateusz Hypertension Original Articles High blood pressure is a risk factor for cardiovascular diseases. Ang II (angiotensin II), a key pro-hypertensive hormone, mediates target organ consequences such as endothelial dysfunction and cardiac hypertrophy. S1P (sphingosine-1-phosphate), produced by Sphk1 (sphingosine kinase 1), plays a pivotal role in the pathogenesis of hypertension and downstream organ damage, as it controls vascular tone and regulates cardiac remodeling. Accordingly, we aimed to examine if pharmacological inhibition of Sphk1 using selective inhibitor PF543 can represent a useful vasoprotective and cardioprotective anti-hypertensive strategy in vivo. PF543 was administered intraperitoneally throughout a 14-day Ang II-infusion in C57BL6/J male mice. Pharmacological inhibition of Sphk1 improved endothelial function of arteries of hypertensive mice that could be mediated via decrease in eNOS (endothelial nitric oxide synthase) phosphorylation at T495. This effect was independent of blood pressure. Importantly, PF543 also reduced cardiac hypertrophy (heart to body weight ratio, 5.6±0.2 versus 6.4±0.1 versus 5.9±0.2 mg/g; P<0.05 for Sham, Ang II+placebo, and Ang II+PF543-treated mice, respectively). Mass spectrometry revealed that PF543 elevated cardiac sphingosine, that is, Sphk1 substrate, content in vivo. Mechanistically, RNA-Seq indicated a decreased expression of cardiac genes involved in actin/integrin organization, S1pr1 signaling, and tissue remodeling. Indeed, downregulation of Rock1 (Rho-associated coiled-coil containing protein kinase 1), Stat3 (signal transducer and activator of transcription 3), PKC (protein kinase C), and ERK1/2 (extracellular signal-regulated kinases 1/2) level/phosphorylation by PF543 was observed. In summary, pharmacological inhibition of Sphk1 partially protects against Ang II–induced cardiac hypertrophy and endothelial dysfunction. Therefore, it may represent a promising target for harnessing residual cardiovascular risk in hypertension. Lippincott, Williams & Wilkins 2020-02 2019-12-16 /pmc/articles/PMC7055939/ /pubmed/31838904 http://dx.doi.org/10.1161/HYPERTENSIONAHA.119.13450 Text en © 2019 The Authors. Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.
spellingShingle Original Articles
Józefczuk, Ewelina
Nosalski, Ryszard
Saju, Blessy
Crespo, Eva
Szczepaniak, Piotr
Guzik, Tomasz Jan
Siedlinski, Mateusz
Cardiovascular Effects of Pharmacological Targeting of Sphingosine Kinase 1
title Cardiovascular Effects of Pharmacological Targeting of Sphingosine Kinase 1
title_full Cardiovascular Effects of Pharmacological Targeting of Sphingosine Kinase 1
title_fullStr Cardiovascular Effects of Pharmacological Targeting of Sphingosine Kinase 1
title_full_unstemmed Cardiovascular Effects of Pharmacological Targeting of Sphingosine Kinase 1
title_short Cardiovascular Effects of Pharmacological Targeting of Sphingosine Kinase 1
title_sort cardiovascular effects of pharmacological targeting of sphingosine kinase 1
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055939/
https://www.ncbi.nlm.nih.gov/pubmed/31838904
http://dx.doi.org/10.1161/HYPERTENSIONAHA.119.13450
work_keys_str_mv AT jozefczukewelina cardiovasculareffectsofpharmacologicaltargetingofsphingosinekinase1
AT nosalskiryszard cardiovasculareffectsofpharmacologicaltargetingofsphingosinekinase1
AT sajublessy cardiovasculareffectsofpharmacologicaltargetingofsphingosinekinase1
AT crespoeva cardiovasculareffectsofpharmacologicaltargetingofsphingosinekinase1
AT szczepaniakpiotr cardiovasculareffectsofpharmacologicaltargetingofsphingosinekinase1
AT guziktomaszjan cardiovasculareffectsofpharmacologicaltargetingofsphingosinekinase1
AT siedlinskimateusz cardiovasculareffectsofpharmacologicaltargetingofsphingosinekinase1